In the current U.S. market landscape, significant volatility has been observed as major indices like the Dow Jones and Nasdaq Composite experience sharp declines due to ongoing tariff concerns and uncertainty surrounding Federal Reserve policies. In this environment, identifying high-growth tech stocks requires careful consideration of their resilience to geopolitical tensions and their ability to innovate amidst economic challenges.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.29% | 29.79% | ★★★★★★ |
Arcutis Biotherapeutics | 25.76% | 58.17% | ★★★★★★ |
TG Therapeutics | 26.03% | 37.60% | ★★★★★★ |
Travere Therapeutics | 28.65% | 66.06% | ★★★★★★ |
Alkami Technology | 20.46% | 85.16% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.96% | 58.81% | ★★★★★★ |
TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
AVITA Medical | 27.81% | 55.17% | ★★★★★★ |
Lumentum Holdings | 21.35% | 120.49% | ★★★★★★ |
Ascendis Pharma | 32.85% | 59.73% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★★
Overview: Blueprint Medicines Corporation is a precision therapy company that develops medicines for genomically defined cancers and blood disorders, with a market cap of $5.41 billion.
Operations: Blueprint Medicines generates revenue primarily from its pharmaceuticals segment, amounting to $508.82 million. The company focuses on developing targeted therapies for specific cancer and blood disorder profiles.
Blueprint Medicines has demonstrated a robust trajectory in addressing complex medical conditions, notably with its AYVAKIT® treatment showing long-term efficacy in systemic mastocytosis. Recent financials reveal a significant revenue jump to $508.82 million, up from $249.38 million the previous year, reflecting a 22.4% annual growth rate. Moreover, the company forecasts an aggressive 45% revenue increase for 2025, positioning it as a dynamic entity within the biotech sector despite current unprofitability and substantial R&D expenses aimed at groundbreaking medical innovations.
Learn about Blueprint Medicines' historical performance.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Jabil Inc. offers global manufacturing services and solutions, with a market cap of $14.50 billion.
Operations: The company generates revenue through its comprehensive manufacturing services and solutions offered globally. With a market cap of $14.50 billion, Jabil Inc. operates across various industries, providing end-to-end supply chain and product management services that drive its financial performance.
Jabil's recent launch of 1.6T transceivers, designed to support high-speed data transfers essential for AI and cloud computing, underscores its strategic alignment with burgeoning tech demands. This product expansion complements their robust R&D focus, where they invested $1.2 billion last year, enhancing their capabilities in high-performance sectors. Despite a challenging fiscal environment with a net income drop to $117 million from $927 million year-over-year and a slight revenue decrease to $6.7 billion, Jabil's commitment to innovation through significant R&D expenditure positions it uniquely within the tech landscape. The company’s forward-looking guidance anticipates revenues up to $27.9 billion for the year, reflecting confidence in its operational resilience and market adaptability.
Gain insights into Jabil's historical performance by reviewing our past performance report.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pure Storage, Inc. provides data storage and management technologies, products, and services both in the United States and internationally, with a market cap of approximately $13.61 billion.
Operations: Pure Storage generates revenue primarily from its computer storage devices, amounting to approximately $3.17 billion. The company's market cap stands at around $13.61 billion, reflecting its significant presence in the data storage and management sector globally.
Pure Storage's recent unveiling of FlashBlade//EXA™, a cutting-edge data storage platform, marks a significant step in addressing the intensive demands of AI and High-Performance Computing (HPC). This innovation is designed to shatter existing metadata bottlenecks, offering an architecture that supports high concurrency and massive metadata operations—key for large-scale AI deployments. Financially, Pure Storage has demonstrated robust growth with a 73.5% increase in earnings over the past year and forecasts suggest a promising revenue trajectory with an expected annual increase of 10.9%. Additionally, the company's strategic share repurchase program underscores its confidence in sustained growth, having recently allocated $250 million towards buying back shares. With R&D investments aligning closely with industry needs and financial strategies geared towards enhancing shareholder value, Pure Storage is poised to maintain its competitive edge in the rapidly evolving tech landscape.
Understand Pure Storage's track record by examining our Past report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:BPMC NYSE:JBL and NYSE:PSTG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。